Phathom Pharma soars after FDA grants 10-year exclusivity shield for stomach drug

Shares of drugmaker Phathom Pharmaceuticals PHAT.O rise 134% to near 7-month high of $11

Co's request to the US FDA to update the "Orange Book" has been approved, granting its stomach infection medication, Voquezna, a 10-year exclusivity period

Stock set for its best day on record, if gains hold

The exclusivity period will prevent other firms from making similar versions of Voquezna

Phathom filed a citizen petition to the FDA last year, seeking this exclusivity

This exclusivity was initially granted to other versions of the drug, Voquezna Paks, which contain the same active ingredient as Voquezna

Exclusivity protection will extend through May 3, 2032

Including session's moves, stock up 31% YTD